A Safety and Efficacy Study of XERMELO® + First-line Chemotherapy in Patients With Advanced Biliary Tract Cancer
Active, not recruiting
Lexicon Pharmaceuticals
Phase 2
2019-03-13
A Phase 2, multicenter, open-label, 2-stage study to assess the safety, tolerability, and
efficacy of XERMELO in combination with first-line (1L) therapy (cisplatin [cis] plus
gemcitabine [gem])
A Safety and Efficacy Study of XERMELO® + First-line Chemotherapy in Patients With Advanced Biliary Tract Cancer
Active, not recruiting
TerSera Therapeutics LLC
Phase 2
2019-03-13
A Phase 2, multicenter, open-label, 2-stage study to assess the safety, tolerability, and
efficacy of XERMELO in combination with first-line (1L) therapy (cisplatin [cis] plus
gemcitabine [gem])
Telotristat Ethyl to Promote Weight Stability in Patients With Advanced Stage Pancreatic Cancer
Recruiting
Lexicon Pharmaceuticals
Phase 2
2019-04-17
This phase II trial studies how well telotristat ethyl works in promoting weight stability in
patients with pancreatic adenocarcinoma that has come back and spread to other places in the
body. Telotristat ethyl may decrease bowel movements which may make patients gain weight.
Stabilizing weight may help patients tolerate chemotherapy better and improve longevity.
Telotristat Ethyl to Promote Weight Stability in Patients With Advanced Stage Pancreatic Cancer
Recruiting
TerSera Therapeutics LLC
Phase 2
2019-04-17
This phase II trial studies how well telotristat ethyl works in promoting weight stability in
patients with pancreatic adenocarcinoma that has come back and spread to other places in the
body. Telotristat ethyl may decrease bowel movements which may make patients gain weight.
Stabilizing weight may help patients tolerate chemotherapy better and improve longevity.
Telotristat Ethyl to Promote Weight Stability in Patients With Advanced Stage Pancreatic Cancer
Recruiting
Emory University
Phase 2
2019-04-17
This phase II trial studies how well telotristat ethyl works in promoting weight stability in
patients with pancreatic adenocarcinoma that has come back and spread to other places in the
body. Telotristat ethyl may decrease bowel movements which may make patients gain weight.
Stabilizing weight may help patients tolerate chemotherapy better and improve longevity.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
